Quince Therapeutics

QNCXPhase 3

South San Francisco, United StatesFounded 2018quincetx.com

Quince Therapeutics is dedicated to addressing the significant unmet medical need in neurodegenerative disorders through its precision medicine approach. The company's strategy centers on its lead program, EQ101, which is advancing through clinical development for Alzheimer's disease, with potential applications in other NLRP3-mediated conditions. Quince leverages its expertise in neuroinflammation biology to build a pipeline of targeted therapeutics, positioning itself in a competitive but high-value market segment. The company operates as a lean, focused organization with key leadership experienced in neuroscience drug development.

Market Cap

$4.5M

Founded

2018

Employees

11-50

Focus

Biotech

QNCX · Stock Price

USD 0.085.89 (-98.66%)

Historical price data

AI Company Overview

Technology Platform

Discovery and development of brain-penetrant small molecule inhibitors targeting the NLRP3 inflammasome to treat neuroinflammatory and inflammatory diseases.

Pipeline Snapshot

8 drugs in pipeline, 4 in Phase 3

Drug	Indication	Stage
Dexamethasone sodium phosphate	Ataxia Telangiectasia	Phase 3
Dexamethasone sodium phosphate	Ataxia Telangiectasia	Phase 3
Dexamethasone	Crohn's Disease	Phase 3
EryDex Low dose DSP + EryDex High dose DSP + Pooled Placebo	Nervous System Disease	Phase 3
Dex 21-P + Placebo	Ulcerative Colitis	Phase 2

Funding History

Total raised: $131M

IPO$86MUndisclosedJul 15, 2020

Series A$45MMorningside VenturesJun 15, 2019

Opportunities

The primary growth opportunity is the successful development of EQ101 for Alzheimer's disease, a multi-billion dollar market with high unmet need.

Success could enable expansion into other lucrative neurodegenerative (Parkinson's, ALS) and systemic inflammatory disease markets.

The oral, small molecule approach offers potential advantages in convenience and cost.

Risk Factors

Key risks include clinical failure of EQ101, the unproven role of NLRP3 inhibition as a primary treatment for Alzheimer's, limited financial runway requiring future dilutive financing, and intense competition in the neurodegenerative disease space from both novel mechanisms and newly approved therapies.

Competitive Landscape

Quince competes with other biotechs developing NLRP3 inhibitors (e.g., NodThera, Novartis/IFM) and all companies developing disease-modifying therapies for Alzheimer's. Its key differentiation is the focus on brain-penetrant NLRP3 inhibitors specifically for CNS disorders, a narrower niche than developers of systemic inhibitors.